Journal article
The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model
AG Jarnicki, H Schilter, G Liu, K Wheeldon, AT Essilfie, JS Foot, TT Yow, W Jarolimek, PM Hansbro
British Journal of Pharmacology | WILEY | Published : 2016
DOI: 10.1111/bph.13573
Abstract
Background and Purpose: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death, often induced by cigarette smoking (CS). It is characterized by pulmonary inflammation and fibrosis that impairs lung function. Existing treatments aim to control symptoms but have low efficacy, and there are no broadly effective treatments. A new potential target is the ectoenzyme, semicarbazide-sensitive mono-amine oxidase (SSAO; also known as vascular adhesion protein-1). SSAO is elevated in smokers’ serum and is a pro-inflammatory enzyme facilitating adhesion and transmigration of leukocytes from the vasculature to sites of inflammation. Experimental Approach: PXS-4728A was develop..
View full abstractGrants
Funding Acknowledgements
This study was supported by grants from the Australian Federal Government Techvoucher and Research in Business schemes and the National Health and Medical Research Council (NHMRC) of Australia. A.G.J. was supported by The Australian Lung Foundation/Boehringer Ingelheim COPD Research Fellowship. P.M.H. is supported by an NHMRC Principal Research Fellowship and a Brawn Fellowship, Faculty of Health & Medicine, University of Newcastle.